|
|
|
|
|
My Recent Searches
|
|
|
|
|
|
|
Pliant Therapeutics, Inc. (PLRX) |
|
|
$0.00 0.00 (0.00%) as of 4:30 Tue 11/30
|
|
Download |
|
|
|
|
Exchange: |
N/A |
Security
Type: |
N/A |
Shares
Out: |
62,906,000 |
Market
Cap: |
N/A |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$ - $ |
|
Level
I Sector: |
N/A |
Level
II Sector: |
N/A |
Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile Pliant Therapeutics is a clinical stage biopharmaceutical company focused on discovering and developing therapies for the treatment of fibrosis and related diseases. Co.'s focus is on treating fibrosis by inhibiting integrin-mediated activation of TGF-ss. Co.'s main product candidate, PLN-74809, is a dual selective inhibitor of avss6 and avss1 integrins that Co. is developing for the treatment of idiopathic pulmonary fibrosis and primary sclerosing cholangitis. Co.'s second product candidate, PLN-1474, is a selective inhibitor of avss1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis, which Co. has partnered with Novartis Institutes for Biomedical Research, Inc.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
0 |
Total Buy Value |
$0 |
$0 |
$0 |
$0 |
Total People Bought |
0 |
0 |
0 |
0 |
Total Buy Transactions |
0 |
0 |
0 |
0 |
Total Shares Sold |
0 |
60,780 |
243,411 |
2,717,120 |
Total Sell Value |
$0 |
$1,047,240 |
$4,403,797 |
$18,310,240 |
Total People Sold |
0 |
5 |
5 |
6 |
Total Sell Transactions |
0 |
5 |
14 |
45 |
End Date |
2024-02-11 |
2023-11-10 |
2023-05-12 |
2022-05-12 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Lefebvre Eric |
Chief Medical Officer |
|
2023-07-14 |
4 |
A |
$0.00 |
$0 |
D/D |
43,750 |
189,536 |
|
- |
|
Cummings Keith Lamont |
Chief Financial Officer |
|
2023-07-14 |
4 |
A |
$0.00 |
$0 |
D/D |
38,750 |
223,770 |
|
- |
|
Coulie Bernard |
President and CEO |
|
2023-07-14 |
4 |
A |
$0.00 |
$0 |
D/D |
137,500 |
412,253 |
|
- |
|
Cummings Keith Lamont |
Chief Financial Officer |
|
2023-06-13 |
4 |
OE |
$2.08 |
$63,960 |
D/D |
30,750 |
185,020 |
|
- |
|
Cummings Keith Lamont |
Chief Financial Officer |
|
2023-06-09 |
4 |
OE |
$2.08 |
$12,064 |
D/D |
5,800 |
154,270 |
|
- |
|
Coulie Bernard |
President and CEO |
|
2023-02-03 |
4 |
AS |
$33.36 |
$504,200 |
D/D |
(15,000) |
240,112 |
|
- |
|
Coulie Bernard |
President and CEO |
|
2023-02-03 |
4 |
OE |
$6.22 |
$93,300 |
D/D |
15,000 |
255,112 |
|
- |
|
Coulie Bernard |
President and CEO |
|
2023-02-02 |
4 |
AS |
$34.13 |
$513,230 |
D/D |
(15,000) |
240,112 |
|
- |
|
Coulie Bernard |
President and CEO |
|
2023-02-02 |
4 |
OE |
$6.22 |
$93,300 |
D/D |
15,000 |
255,112 |
|
- |
|
Coulie Bernard |
President and CEO |
|
2023-02-01 |
4 |
AS |
$34.15 |
$515,767 |
D/D |
(15,000) |
240,112 |
|
- |
|
Coulie Bernard |
President and CEO |
|
2023-02-01 |
4 |
OE |
$6.22 |
$93,300 |
D/D |
15,000 |
255,112 |
|
- |
|
Coulie Bernard |
President and CEO |
|
2023-01-31 |
4 |
AS |
$34.92 |
$523,755 |
D/D |
(15,000) |
240,112 |
|
- |
|
Coulie Bernard |
President and CEO |
|
2023-01-31 |
4 |
OE |
$2.08 |
$49,669 |
D/D |
15,000 |
255,112 |
|
- |
|
Coulie Bernard |
President and CEO |
|
2023-01-30 |
4 |
AS |
$33.98 |
$512,116 |
D/D |
(15,000) |
240,112 |
|
- |
|
Coulie Bernard |
President and CEO |
|
2023-01-30 |
4 |
OE |
$2.08 |
$31,200 |
D/D |
15,000 |
255,112 |
|
- |
|
Coulie Bernard |
President and CEO |
|
2023-01-27 |
4 |
AS |
$35.09 |
$351,255 |
I/I |
(10,000) |
409,317 |
|
- |
|
Coulie Bernard |
President and CEO |
|
2023-01-27 |
4 |
AS |
$35.42 |
$535,289 |
D/D |
(15,000) |
240,112 |
|
- |
|
Coulie Bernard |
President and CEO |
|
2023-01-27 |
4 |
OE |
$2.08 |
$31,200 |
D/D |
15,000 |
255,112 |
|
- |
|
Coulie Bernard |
President and CEO |
|
2023-01-26 |
4 |
AS |
$35.10 |
$526,425 |
I/I |
(15,000) |
419,317 |
|
- |
|
Coulie Bernard |
President and CEO |
|
2023-01-26 |
4 |
AS |
$35.29 |
$529,367 |
D/D |
(15,000) |
240,112 |
|
- |
|
Coulie Bernard |
President and CEO |
|
2023-01-26 |
4 |
OE |
$2.08 |
$31,200 |
D/D |
15,000 |
255,112 |
|
- |
|
Coulie Bernard |
President and CEO |
|
2023-01-25 |
4 |
A |
$0.00 |
$0 |
D/D |
146,300 |
240,112 |
|
- |
|
Cummings Keith Lamont |
Chief Financial Officer |
|
2023-01-25 |
4 |
A |
$0.00 |
$0 |
D/D |
54,000 |
138,424 |
|
- |
|
Lefebvre Eric |
Chief Medical Officer |
|
2023-01-25 |
4 |
A |
$0.00 |
$0 |
D/D |
57,000 |
133,926 |
|
- |
|
Ouimette Mike |
General Counsel & Corp. Secy |
|
2023-01-25 |
4 |
A |
$0.00 |
$0 |
D/D |
39,000 |
44,947 |
|
- |
|
133 Records found
|
|
Page 2 of 6 |
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Acquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|